Advantages of Proactive Therapeutic Drug Monitoring in a Prospective Cohort of Children With Inflammatory Bowel Disease Treated With Anti-Tumour Necrosis Factor. Issue 4 (3rd April 2022)

• Record Type: Journal Article
• Authors: Gasparetto, Marco; Burgess, Natasha; Naik, Sandhia; Studart, Dominic; Kadir, Ahmed; Croft, Nick; Sanderson, Ian; Deb, Protima
• Is Part Of: Journal of pediatric gastroenterology and nutrition. Volume 74:Issue 4(2022)
• Page Start: 484
• Page End: 489
• Publication Date: 2022-04-03
• Subjects: anti-tumour necrosis factor -- inflammatory bowel disease -- proactive -- reactive -- therapeutic drug monitoring; Children -- Nutrition -- Periodicals; Pediatric gastroenterology -- Periodicals; Infants -- Nutrition -- Periodicals; Nutrition disorders in children -- Periodicals; Child Nutrition -- Periodicals; Digestive System -- growth & development -- Periodicals; Gastrointestinal Diseases -- Periodicals; Infant Nutrition -- Periodicals; Nutrition Disorders -- Periodicals; Child; 618.923
• DOI: 10.1097/MPG.0000000000003389
• Languages: English
• ISSNs: 0277-2116

Abstract

Abstract : ABSTRACT: Few studies have addressed whether proactive therapeutic drug monitoring (TDM) results in improved clinical outcomes in children with inflammatory bowel disease (IBD) treated with anti-tumour necrosis factor. The aim of this study was to investigate the impact of using proactive TDM in this patient group. Pilot single-centre observational study to accrue data on patients managed with proactive TDM. More patients in the proactive TDM cohort were managed by escalating the infliximab (IFX) regime ( P < 0.001). The need for switching to different biologics was significantly lower in this patient group ( P < 0.001). The introduction of proactive TDM resulted in a significant reduction of patients requiring switch of their primary biologic. The results of this study are indicators that proactive TDM offers a better method of managing children with IBD on IFX therapy.